Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Boosted By Australian Initiatives

Market Share Close To A Quarter Following Educational Efforts

Executive Summary

Australia has reaped the rewards of outreach efforts on biosimilars, according to the country’s GBMA off-patent industry association, with the market share enjoyed by biosimilar medicines rising significantly in the two years since Australia’s government issued a grant for educational activities. In future, the GBMA’s Biosimilar Awareness Week could be used as the model for a global biosimilars campaign backed by the IGBA.

You may also be interested in...



Australia Rolls Out Second ‘Biosimilars Week’

A series of educational events and messages are being rolled out by Australia’s GBMA industry association as part of “Biosimilar Awareness Week.”

Australian Initiative Aims To Educate On Biosimilars

Australia’s GBMA is rolling out its second annual “Biosimilar Week” later this month as part of a three-year education program being pursued by the association and industry stakeholders.

Australia issues grant to bolster biosimilars

A ‘biosimilar education grant’ of A$5 million (US$3.8 million) has been awarded by Australia’s government to the country’s Generic and Biosimilar Medicines Association (GBMA) to “complement and extend” activities being undertaken as part of the country’s biosimilar awareness initiative.

Topics

UsernamePublicRestriction

Register

LL1133377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel